NAD Augmentation to Treat Diabetes Kidney Disease: A Randomized Controlled Trial
Latest Information Update: 29 Apr 2026
At a glance
- Drugs MIB-626 (Primary)
- Indications Diabetic neuropathies
- Focus Pharmacokinetics
Most Recent Events
- 13 Apr 2026 Planned number of patients changed from 140 to 156.
- 18 Feb 2026 Planned End Date changed from 1 Jul 2026 to 31 Mar 2027.
- 18 Feb 2026 Planned primary completion date changed from 31 Dec 2025 to 30 Nov 2027.